Clinical Trial Update: Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of a fixed-dose combination of saxagliptin/metformin XR compared with separate Onglyza and Glucophage XR; results were posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Glucophage XR (metformin hydrochloride extended-release)
• Onglyza (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2011-05-17